Multiple clinical trials demonstrate Cialis’s positive impact on lower urinary tract symptoms (LUTS) associated with benign prostatic hyperplasia (BPH). These studies show significant improvements in various urinary parameters. For example, the International Prostate Symptom Score (IPSS), a widely used measure of BPH symptoms, showed a clinically meaningful reduction in many trials.
One study reported a mean IPSS reduction of approximately 4 to 5 points in men treated with Cialis compared to placebo. This translates to substantial relief for many patients. Improvements were observed across several key symptoms, including urinary frequency, urgency, hesitancy, and weak stream.
Furthermore, research indicates improvements in urinary flow rate (Qmax), a direct measure of how quickly urine exits the bladder. Cialis treatment has shown increases in Qmax, signifying improved bladder emptying. The magnitude of this improvement varied across trials, but a consistent trend toward increased flow was observed.
Specific numerical data from individual trials should be consulted for precise details on symptom improvement in different patient subgroups. Always consult your doctor to discuss whether Cialis is appropriate for your individual needs and medical history.
